
Retatrutide trials: which studies exist, and what each one tested
A trial-by-trial index of the retatrutide record: the completed phase 1b and phase 2 studies in obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, the TRIUMPH and TRANSCEND phase 3 programmes, and what each publication can and cannot establish.
The retatrutide trials on record fall into two groups: completed phase 1 and phase 2 studies that report results in a defined population, and the phase 3 programme, whose TRIUMPH studies have been published so far as rationale and design, alongside a first phase 3 readout in type 2 diabetes published in 2026. This page indexes both groups by phase and population so a reader can see which questions have actually been tested and which remain plans.
Key takeaways
- Three publications anchor this map: a 48-week phase 2 trial in 338 adults with obesity, a phase 2a MASLD substudy of 98 participants sharing the same registration, and a design paper for four phase 3 TRIUMPH trials.
- The MASLD substudy drew its participants from the obesity trial, so it is a nested analysis in one population rather than an independent replication.
- TRIUMPH comprises four phase 3 studies with over 5,800 participants across obesity, obstructive sleep apnoea (OSA) and knee osteoarthritis (OA), and the published paper reports design only.
- A second phase 3 programme, TRANSCEND, covers type 2 diabetes and chronic kidney disease, and the research record describes TRANSCEND-T2D-1 as the first published phase 3 readout.
- A batch certificate documents one batch of material. It cannot describe a trial, a population or an end point.
How the retatrutide trial record divides
A phase 3, or registrational, trial is the larger programme whose design a regulator would assess, and a design paper describes such a programme without reporting what it found. The retatrutide record contains both kinds of document, and they read very differently.
The research record dates the compound's first description to preclinical pharmacology and phase 1 work in 2022, with randomised phase 2 trials in obesity, type 2 diabetes and MASLD following. It orders 15 studies by strength of design, which is why this page does not repeat the citation list: the trial index below covers study design and scope, and the research record carries the findings themselves.
The asymmetry in the literature matters more than it first appears. Two phase 2 publications report measured results in specific groups. The TRIUMPH paper sets out four studies, their populations and their end points without reporting a single outcome. The TRIUMPH paper reports rationale and design only, and none of its four studies contributes outcome data in that publication.
Completed phase 1 and phase 2 studies
The largest completed study is a phase 2, double-blind, randomised, placebo-controlled trial in adults with a body-mass index of 30 or higher, or of 27 to under 30 alongside at least one weight-related condition. It enrolled 338 adults over 48 weeks and set its primary end point as the percentage change in body weight from baseline to 24 weeks. Secondary end points covered the change at 48 weeks, the proportion reaching 5%, 10% and 15% weight reduction, and safety. The trial is registered as NCT04881760 and was funded by Eli Lilly.
The MASLD paper is a substudy rather than a separate trial. It randomised 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat, drawn from that same study, over a 48-week period, with the mean relative change in liver fat at 24 weeks as its primary objective. It names the same registration, NCT04881760, which is the detail that shows the two publications describe one parent study and one randomisation.
The research record adds two earlier entries that do not have a full publication in the source set for this page: a phase 1b randomised, placebo-controlled trial in 72 adults with type 2 diabetes over 12 weeks, and a phase 2 trial in 281 adults with type 2 diabetes over 36 weeks that was both placebo- and dulaglutide-controlled. The table places all four completed studies beside the phase 3 design paper.
| Publication or record | Phase | Population | Participants | Length | What the publication reports |
|---|---|---|---|---|---|
| Obesity trial (PMID 37366315) | Phase 2 | Adults with a body-mass index of 30 or higher, or 27 to under 30 with a weight-related condition | 338 | 48 weeks | Primary end point at 24 weeks, secondary end points and safety |
| MASLD substudy (PMID 38858523) | Phase 2a | MASLD with 10% or more liver fat, drawn from the obesity trial | 98 | 48 weeks | Liver fat change at 24 weeks, from the same registration |
| Type 2 diabetes trial (research record) | Phase 2 | Adults with type 2 diabetes | 281 | 36 weeks | Placebo- and dulaglutide-controlled comparison |
| Phase 1b trial (research record) | Phase 1b | Adults with type 2 diabetes | 72 | 12 weeks | Multiple ascending amounts, randomised and placebo-controlled |
| TRIUMPH-1 to TRIUMPH-4 (PMID 41090431) | Phase 3 | Obesity with OSA and/or knee OA protocols nested; cardiovascular disease; knee OA | Over 5,800 across the four trials | Trial duration is not reported in the abstract supplied for the design paper. | Rationale and design only, no outcome data |
What each publication can and cannot establish
The useful discipline with this record is to ask what each document was built to show. A phase 2 report speaks about the group it randomised. A design paper speaks about a plan. Neither substitutes for the other, and neither covers the populations the other studied.
The four checks below follow from the designs themselves rather than from any interpretation of the results.
- 01
A phase 2 result belongs to its population
The obesity trial randomised adults who met a body-mass index threshold, with or without a weight-related condition. What it measured applies to that group, and not automatically to adults with type 2 diabetes or with MASLD.
- 02
The MASLD substudy is nested, not independent
Its 98 participants came from the obesity trial and it carries the same registration. A nested analysis provides detail on a subgroup; it does not provide a second, independent test of the same question.
- 03
A design paper is a protocol, not a finding
The TRIUMPH paper states populations, end points and how the type I error rate is controlled. It reports no outcome, so it cannot be cited as evidence that anything worked or did not.
- 04
One programme's readout does not describe another
A result published from a type 2 diabetes programme says nothing about the OSA or knee OA protocols, which measure different end points in different populations.
The TRIUMPH phase 3 programme
The TRIUMPH design paper describes four phase 3, multicentre, randomised, double-blind studies comparing retatrutide with placebo in over 5,800 participants. The programme uses a basket design, meaning one overarching trial structure carries several disease-specific protocols so that each can be analysed independently.
The primary end point is percentage change in body weight for the weight-management analyses, change in the apnoea-hypopnoea index for the OSA protocols, and, for the knee OA trial, a primary end point that includes change in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score. The paper states that the basket structure allows independent analysis of the weight-management, OSA and OA studies with the type I error rate controlled at alpha = 0.05, split between the overarching weight-management analysis and each basket.
The research record notes that, as of August 2026, TRIUMPH-1 to TRIUMPH-4 had published rationale and design papers only, with results disclosed by the sponsor as topline announcements rather than peer-reviewed publications. That distinction is the reason this page describes the programme in terms of design.
TRIUMPH-1 and TRIUMPH-2
Two weight-management basket trials, with OSA and/or knee OA protocols nested inside them.
TRIUMPH-3
A weight-management trial in a population with cardiovascular disease.
TRIUMPH-4
A stand-alone knee OA trial, outside the basket structure.
The TRANSCEND programme in type 2 diabetes and kidney outcomes
TRIUMPH is not the only late-stage programme in the record. The research record describes a parallel TRANSCEND programme covering type 2 diabetes and chronic kidney disease, and names TRANSCEND-T2D-1 as the first published phase 3 readout for the compound: a double-blind, randomised trial in 537 adults with type 2 diabetes over 40 weeks, published in 2026, with HbA1c change as the reported glycaemic measure.
A second entry, TRANSCEND-CKD, is a phase 2b mechanistic trial with 146 randomised participants with chronic kidney disease. Its primary end point was change in measured glomerular filtration rate by iohexol clearance from baseline to week 24. The publication covers design and baseline characteristics, so it belongs with the design documents rather than with the completed results.
Read together, the two programmes show why 'phase 3 retatrutide trial' is not a single thing. One phase 3 study has a peer-reviewed readout in type 2 diabetes; four obesity, sleep apnoea and osteoarthritis studies have design papers. Both statements can be true at once, and the research record is the place where each entry is dated and sourced.
What a batch certificate adds, and what it cannot
The product record carries a certificate for batch 26138, tested 10 Aug 2026 by the Brown Institute of Biomolecular Research, with a purity of 99.86% and the results string "RT: 30mg | Purity: 99.86%". It is a report from a named laboratory outside AKH, ordered by the manufacturer, and it documents that batch.
That is its whole scope. A certificate cannot state which trial a material was made for, which population was studied or what an end point measured.
Common questions.
- What retatrutide trials have been published?
Three publications anchor the record: a 48-week phase 2 trial in 338 adults with obesity (PMID 37366315), a phase 2a MASLD substudy of 98 participants sharing the same registration (PMID 38858523), and a 2026 design paper for four TRIUMPH phase 3 trials (PMID 41090431). The research record adds a phase 1b study, a phase 2 type 2 diabetes trial and the TRANSCEND entries.
- Is there a phase 3 retatrutide trial?
Yes, four of them sit in the TRIUMPH programme: TRIUMPH-1 and TRIUMPH-2 as weight-management basket trials with sleep apnoea and osteoarthritis protocols nested inside, TRIUMPH-3 in a population with cardiovascular disease, and TRIUMPH-4 in knee osteoarthritis, together covering over 5,800 participants. A separate phase 3 programme, TRANSCEND, includes TRANSCEND-T2D-1, described in the research record as the first published phase 3 readout.
- What is the TRIUMPH trial programme testing?
It evaluates retatrutide across obesity and two related complications, obstructive sleep apnoea and knee osteoarthritis. The primary end point is percentage change in body weight for weight management, change in the apnoea-hypopnoea index for the sleep apnoea protocols, and, for knee osteoarthritis, a primary end point that includes change in a knee osteoarthritis pain subscale score. The published paper covers rationale and design only.
- What can a phase 2 trial show that a design paper cannot?
A phase 2 trial reports a measured result in a defined population, such as the change in liver fat at 24 weeks in 98 participants with MASLD. A design paper reports what will be measured, in whom, and how the error rate is controlled. It contains no outcome data, so it cannot be read as evidence of an effect in either direction.
Sources
- 01Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- 02Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- 03Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
- 04Buy Retatrutide 30mg (GLP-3, Reta): Price & COA · AKH BioLabs
- 05Retatrutide research — published studies and evidence · AKH BioLabs